RARE - Ultragenyx Pharmaceutical Inc.
About Ultragenyx Pharmaceutical Inc. (https://www.ultragenyx.com)
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Emil D. Kakkis | Founder, President, Chief Executive Officer & Director | 1960 | $1,193,241 USD |
| Erik Harris | Executive Vice President & Chief Commercial Officer | 1970 | $925,255 USD |
| John Richard Pinion | Chief Quality Operations Officer & Executive Vice President of Translational Sciences | 1966 | $923,934 USD |
| Eric Crombez | Chief Medical Officer & Executive Vice President | 1973 | $882,356 USD |
| Howard Horn | Executive Vice President of Corporate Strategy & Chief Financial Officer | 1979 | $846,010 USD |
| Karah Herdman Parschauer | Chief Legal Officer & Executive Vice President of Corporate Affairs | 1978 | $819,872 USD |
| Eric Olson | Chief Business Officer & Executive Vice President | – | $714,838 USD |
| Dennis Karl Huang | Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations | 1965 | $331,330 USD |
| Aaron Olsen | Senior Vice President of Corporate Strategy & Finance | – | – |
| Alison Skrinar | Vice President of Clinical Outcomes Research and Evaluation | 1970 | – |
| Arjun Natesan | Vice President of Translational Research | – | – |
| Ernie W. Meyer | Chief Human Resources Officer & Executive Vice President | 1965 | – |
| Paul Wickman | Vice President of Intellectual Property | – | – |
| Theodore A. Huizenga | Senior Vice President, Corporate Controller & Principal Accounting Officer | 1971 | – |
| Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | 1965 | – |